Skip to content
OpenCapital
Get started

United Therapeutics UTHR Unituxin — Gross Profit

Other product segments

Tyvaso DPI
$247.1M-2.9%
Orenitram
$128.2M+14.1%
Nebulized Tyvaso
$118.6M-23.6%
Remodulin
$110.5M-11.2%
Adcirca
$1.9M-44.1%

Similar metrics at other companies

Hubbell logo
HUBBUtility Solutions — Total Gross Profit
$317.1M+16.7%
Centuri Holdings logo
CTRIUnion Electric — Gross Profit
$18.23M+54.4%
CF Industries logo
CFUAN — Gross Profit
$250M+76.1%
Matrix Service Company logo
MTRXUtility and Power Infrastructure — Gross Profit
$8.16M+47.4%
Block logo
XYZGross Profit
$2.91B+27.1%
Cintas logo
CTASUniform rental and facility services — Gross Profit
$1.09B+8.2%

Other financials

Income statement

See full
Revenue$781.5M-1.6%
Gross profit$648.1M-7.7%
Operating income$325.8M-14.9%
Net income$274.9M-14.7%
EPS (diluted)$5.82-12.2%

Balance sheet

See full
Cash & equivalents$1.3B-32.6%
Total debt$12.2M—
Total equity$5.9B-13.3%
Total assets$6.7B-13.3%

Cash flow

See full
Operating cash flow$463.3M+0.5%
CapEx$100.8M+34.6%
Free cash flow$362.5M-6.2%

Valuation

See full
Market cap$23B+84.1%
P/E17.9×+7.8×
P/S7.3×+3.2×

Profitability

See full
Gross margin86.6%-2.4pp
Operating margin45.3%-1.6pp
Net margin40.6%+0.2pp
FCF margin32.1%-5.6pp

Returns & leverage

See full
Return on equity20.3%+0.3pp
Debt / equity0×—
Current ratio4.8×-0.7×

Where this comes from

Reported directly by United Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:GrossProfit.

The official record: United Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about United Therapeutics's unituxin — gross profit.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is United Therapeutics's unituxin — gross profit?
United Therapeutics (UTHR) reported unituxin — gross profit of $48.6M in Q1 2026.
How has United Therapeutics's unituxin — gross profit changed year-over-year?
United Therapeutics's unituxin — gross profit decreased by 8.3% year-over-year, from $53M to $48.6M.
What is the long-term trend for United Therapeutics's unituxin — gross profit?
Over 4 years (2021 to 2025), United Therapeutics's unituxin — gross profit has grown at a 2.7% compound annual growth rate (CAGR), from $188.1M to $209.3M.
What does unituxin — gross profit mean?
This metric represents the profit a specific product line generates after deducting the direct costs of production from its total revenue. It serves as a primary indicator of the product's inherent profitability before accounting for operating expenses like R&D or marketing.